The Global Multi-omics Solution for Precision Oncology

Indivumed Services was acquired by Crown Bioscience from Indivumed GmbH in April 2023.

The original company was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy.

As an integrated global oncology company our experts leverage the highest quality biobank to develop a true picture of cancer. Our three divisions operate holistically with one another for the generation, characterization, and analysis of biologic samples from human cancer patients.

Indivumed Services is headquartered in Hamburg, Germany, with a US-based subsidiary in Frederick, Maryland, USA  and a global clinical network.

At Indivumed Services we are united by a shared responsibility:
using our unique expertise and skill sets to work toward individualized cancer diagnosis and treatment for every patient.


About Crown Bioscience

wr-crown-logo-2021-v1[1]Headquartered in California, US, Crown Bioscience is a global contract research organization (CRO) providing discovery, preclinical and translational platforms and services to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases.

We are known for our high-quality and expansive in vivo, in vitro, and ex vivo preclinical models, and partner with our clients to quantify the efficacy and pharmacological profile of their drug candidate(s) before they move into the clinic. We aim to deliver superior drug candidates to ensure that patients get the right treatment at the right time.

Crown Bioscience is part of the JSR Life Sciences group of companies. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 14 facilities across the United States, Europe, and Asia.

For more information or to get in touch, please visit